Apolipoprotein M likely extends its anti-atherogenesis via anti-inflammation

Medical Hypotheses

Volumn 69, Issue 1, 2007, Pages 136-140

  Huang, Xian sheng ^a   Zhao, Shui ping ^a   Hu, Min ^a   Luo, Yang ping ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN M; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BODY MASS; CHOLESTEROL METABOLISM; CHROMOSOME 6; DRUG ACTIVITY; HISTOCOMPATIBILITY COMPLEX; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LIPID METABOLISM; NONHUMAN; PRIORITY JOURNAL;

APOLIPOPROTEINS; ATHEROSCLEROSIS; HUMANS; IMMUNITY, NATURAL; IMMUNOLOGIC FACTORS; INFLAMMATION; MODELS, CARDIOVASCULAR; MODELS, IMMUNOLOGICAL;

EID: 34248208748     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.10.052     Document Type: Article

References (31)

1. Xu N., and Dahlback B. A novel human apolipoprotein (apoM). J Biol Chem 274 44 (1999) 31286-31290
2. Zhang X.Y., Dong X., Zheng L., et al. Specific tissue expression and cellular localization of human apolipoprotein M as determined by in situ hybridization. Acta Histochem 105 1 (2003) 67-72
3. Wolfrum C., Poy M.N., and Stoffel M. Apolipoprotein M is required for preβ-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. Nat Med 11 4 (2005) 418-422
4. Luo G., Zhang X., Nilsson-Ehle P., et al. Apolipoprotein M. Lipids Health Dis 3 (2004) 21
5. Navab M., Berliner J.A., Subbanagounder G., et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 21 4 (2001) 481-488
6. Faber K., Axler O., Dahlback B., et al. Characterization of apoM in normal and genetically modified mice. J Lipid Res 45 7 (2004) 1272-1278
7. Duan J., Dahlback B., and Villoutreix B.O. Proposed lipocalin fold for apolipoprotein M based on bioinformatics and site-directed mutagenesis. FEBS Lett 499 (2001) 127-132
8. Zhang X.Y., Dong X., Zheng L., Luo G.H., Liu Y.H., Ekstrom U., et al. Specific tissue expression and cellular localization of human apolipoprotein M as determined by in situ hybridization. Acta Histochem 105 (2003) 67-72
9. Zhang X.Y., Jiao G.Q., Hurtig M., et al. Expression pattern of apolipoprotein M during mouse and human embryogenesis. Acta Histochem 106 2 (2004) 123-128
10. Faber K., Hvidberg V., Moestrup S.K., et al. Megalin is a receptor for apolipoprotein M, and kidney-specific megalin-deficiency confers urinary excretion of apolipoprotein M. Mol Endocrinol 20 1 (2006) 212-218
11. Xu N., Nilsson-Ehle P., and Ahren B. Suppression of apolipoprotein M expression and secretion in alloxan-diabetic mouse: partial reversal by insulin. Biochem Biophys Res Commun 342 4 (2006) 1174-1177
12. Xu N., Nilsson-Ehle P., Hurtig M., et al. Both leptin and leptin-receptor are essential for apolipoprotein M expression in vivo. Biochem Biophys Res Commun 321 4 (2004) 916-921
13. Xu N., Zhang X.Y., Dong X., et al. Effects of platelet-activating factor, tumor necrosis factor, and interleukin-alpha on the expression of apolipoprotein M in HepG2 cells. Biochem Biophys Res Commun 292 4 (2002) 944-950
14. Richter S., Shih D.Q., Pearson E.R., et al. Regulation of apolipoprotein M gene expression by MODY3 gene hepatocyte nuclear factor-1alpha: haploinsufficiency is associated with reduced serum apolipoprotein M levels. Diabetes 52 12 (2003) 2989-2995
15. Xu N., Ahren B., Jiang J., et al. Down-regulation of apolipoprotein M expression is mediated by phosphatidylinositol 3-kinase in HepG2 cells. Biochim Biophys Acta 1761 2 (2006) 256-260
16. Xu N., Hurtig M., Zhang X.Y., et al. Transforming growth factor-beta down- regulates apolipoprotein M in HepG2 cells. Biochim Biophys Acta 1683 1-3 (2004) 33-37
17. Xu N., Nilsson-Ehle P., and Ahren B. Correlation of apolipoprotein M with leptin and cholesterol in normal and obese subjects. J Nutr Biochem 15 10 (2004) 579-582
18. Smith Jr. S.C. Current and future directions of cardiovascular risk prediction. Am J Cardiol 97 2A (2006) 28A-32A
19. Leiter L.A., and Fitchett D. Optimal care of cardiovascular disease and type 2 diabetes patients: shared responsibilities between the cardiologist and diabetologist. Atheroscler Suppl 7 1 (2006) 37-42
20. Burger D., and Dayer J.M. High-density lipoprotein-associated apolipoprotein A-I: the missing link between infection and chronic inflammation?. Autoimmun Rev 1 1-2 (2002) 111-117
21. Garber D.W., Handattu S.P., Datta G., et al. Atherosclerosis and vascular disease: effects of peptide mimetics of apolipoproteins. Curr Pharm Biotechnol 7 4 (2006) 235-240
22. Charlton-Menys V., and Durrington P. Apolipoproteins AI and B as therapeutic targets. J Intern Med 259 5 (2006) 462-472
23. Archunan G., Kamalakkannan S., Achiraman S., and Rajkumar R. Identification of glandular (preputial and clitoral) proteins in house rat (Rattus rattus) involved in pheromonal communication. Indian J Exp Biol 42 10 (2004) 1032-1035
24. Flower D.R. The lipocalin protein family: structure and function. Biochem J 318 Pt 1 (1996) 1-14
25. Xu S., and Venge P. Lipocalins as biochemical markers of disease. Biochim Biophys Acta 1482 1-2 (2000) 298-307
26. Luo G., Hurtig M., Zhang X., et al. Leptin inhibits apolipoprotein M transcription and secretion in human hepatoma cell line, HepG2 cells. Biochim Biophys Acta 1734 2 (2005) 198-202
27. Liang C.P., and Tall A.R. Transcriptional profiling reveals global defects in energy metabolism, lipoprotein, and bile acid synthesis and transport with reversal by leptin treatment in ob/ob mouse liver. J Biol Chem 276 (2001) 49066-49076
28. Corrado E., and Novo S. Role of inflammation and infection in vascular disease. Acta Chir Belg 105 6 (2005) 567-579
29. Libby P., and Theroux P. Pathophysiology of coronary artery disease. Circulation 111 25 (2005) 3481-3488
30. Schmidt A., Geigenmuller S., Volker W., et al. The antiatherogenic and antiinflammatory effect of HDL-associated lysosphingolipids operates via Akt → NF-κB signalling pathways in human vascular endothelial cells. Basic Res Cardiol 101 2 (2006) 109-116
31. Rohrer L., Hersberger M., and von Eckardstein A. High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease. Curr Opin Lipidol 15 3 (2004) 269-278